Adding Bevacizumab to FOLFOXIRI Provides Survival Benefit
Adding bevacizumab to FOLFOXIRI provided significant benefit in progression-free and overall survival in metastatic colorectal cancer.
Adding bevacizumab to FOLFOXIRI (5-fluorouracil, leucovorin, oxaliplatin, irinotecan) provided significant benefit in progression-free and overall survival compared with FOLFOXIRI alone as frontline treatment for patients with metastatic colorectal cancer (mCRC), a propensity score-adjusted analysis published in the journal Annals of Oncology has shown.1
Although FOLFOXIRI plus bevacizumab is a valid option as upfront treatment for patients with mCRC, there are no randomized head-to-head trials evaluating the impact of adding immunotherapy to the chemotherapy regimen. Therefore, researchers sought to conduct a propensity score-adjusted analysis from 2 randomized clinical trials.
For the study, researchers analyzed data from 122 patients with mCRC who received first-line FOLFOXIRI in the phase 3 trial and 252 patients who received first-line FOLFOXIRI plus bevacizumab.
Of note, patients in the FOLFOXIRI group were more likely to have had an ECOG performance status of 1 or 2, a high Köhne score, metachronous and liver-limited disease, previously received adjuvant treatments, and their primary tumors resected.
Results showed that median progression-free survival was 12.3 months in the chemoimmunotherapy group compared with 10.0 months in the chemotherapy alone group (propensity score-adjusted HR, 0.74; 95% CI, 0.59 - 0.94; P = .013).
Median overall survival was 29.8 months and 23.6 months, respectively (propensity score-adjusted HR, 0.72; 95% CI, 0.56 - 0.93; P = .014). Multivariate analyses also demonstrated a significantly longer overall and progression-free survival with FOLFOXIRI plus bevacizumab compared with FOLFOXIRI (P = .030 and P = .013, respectively).
RELATED: Improved Screening, Risk Assessment Needed for Colorectal Cancer in Younger Adults
However, researchers found no significant differences in response rate, early response rate, or median depth of response.
The findings ultimately support the use of FOLFOXIRI plus bevacizumab as first-line treatment for patients with mCRC.
- Cremolini C, Loupakis F, Masi G, et al. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials [published online ahead of print February 9, 2016]. Ann Oncol. doi: 10.1093/annonc/mdw052.